EMA reviewing Samsung Bioepis' Humira biosimilar

Samsung Bioepis Co. Ltd. said EMA accepted for review an MAA for SB5, a biosimilar

Read the full 157 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE